Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

386 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.
Portnow J, Frankel P, Koehler S, Twardowski P, Shibata S, Martel C, Morgan R, Cristea M, Chow W, Lim D, Chung V, Reckamp K, Leong L, Synold TW. Portnow J, et al. Among authors: chung v. Cancer Chemother Pharmacol. 2012 Feb;69(2):505-14. doi: 10.1007/s00280-011-1721-x. Epub 2011 Aug 18. Cancer Chemother Pharmacol. 2012. PMID: 21850464 Free PMC article. Clinical Trial.
A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.
Chao J, Synold TW, Morgan RJ Jr, Kunos C, Longmate J, Lenz HJ, Lim D, Shibata S, Chung V, Stoller RG, Belani CP, Gandara DR, McNamara M, Gitlitz BJ, Lau DH, Ramalingam SS, Davies A, Espinoza-Delgado I, Newman EM, Yen Y. Chao J, et al. Among authors: chung v. Cancer Chemother Pharmacol. 2012 Mar;69(3):835-43. doi: 10.1007/s00280-011-1779-5. Epub 2011 Nov 22. Cancer Chemother Pharmacol. 2012. PMID: 22105720 Free PMC article. Clinical Trial.
Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
Shibata SI, Chung V, Synold TW, Longmate JA, Suttle AB, Ottesen LH, Lenz HJ, Kummar S, Harvey RD, Hamilton AL, O'Neil BH, Sarantopoulos J, LoRusso P, Rudek MA, Dowlati A, Mulkerin DL, Belani CP, Gandhi L, Lau SC, Ivy SP, Newman EM. Shibata SI, et al. Among authors: chung v. Clin Cancer Res. 2013 Jul 1;19(13):3631-9. doi: 10.1158/1078-0432.CCR-12-3214. Epub 2013 May 7. Clin Cancer Res. 2013. PMID: 23653147 Free PMC article. Clinical Trial.
p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses.
Hardwick NR, Carroll M, Kaltcheva T, Qian D, Lim D, Leong L, Chu P, Kim J, Chao J, Fakih M, Yen Y, Espenschied J, Ellenhorn JD, Diamond DJ, Chung V. Hardwick NR, et al. Among authors: chung v. Clin Cancer Res. 2014 Sep 1;20(17):4459-70. doi: 10.1158/1078-0432.CCR-13-3361. Epub 2014 Jul 1. Clin Cancer Res. 2014. PMID: 24987057 Free PMC article. Clinical Trial.
Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors.
Koczywas M, Frankel PH, Synold TW, Lenz HJ, Mortimer JE, El-Khoueiry AB, Gandara DR, Cristea MC, Chung VM, Lim D, Reckamp KL, Lau DH, Doyle LA, Ruel C, Carroll MI, Newman EM. Koczywas M, et al. Among authors: chung vm. Br J Cancer. 2014 Dec 9;111(12):2268-74. doi: 10.1038/bjc.2014.554. Epub 2014 Oct 28. Br J Cancer. 2014. PMID: 25349975 Free PMC article. Clinical Trial.
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group. Wang-Gillam A, et al. Lancet. 2016 Feb 6;387(10018):545-557. doi: 10.1016/S0140-6736(15)00986-1. Epub 2015 Nov 29. Lancet. 2016. PMID: 26615328 Clinical Trial.
p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.
Hardwick NR, Frankel P, Ruel C, Kilpatrick J, Tsai W, Kos F, Kaltcheva T, Leong L, Morgan R, Chung V, Tinsley R, Eng M, Wilczynski S, Ellenhorn JDI, Diamond DJ, Cristea M. Hardwick NR, et al. Among authors: chung v. Clin Cancer Res. 2018 Mar 15;24(6):1315-1325. doi: 10.1158/1078-0432.CCR-17-2709. Epub 2018 Jan 4. Clin Cancer Res. 2018. PMID: 29301826 Free PMC article. Clinical Trial.
386 results